Zurcher Kantonalbank Zurich Cantonalbank Has $19.84 Million Holdings in Cencora, Inc. (NYSE:COR)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Cencora, Inc. (NYSE:COR) by 5.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,056 shares of the company’s stock after purchasing an additional 4,224 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Cencora were worth $19,839,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of COR. Financial Advocates Investment Management increased its stake in Cencora by 4.7% in the second quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after acquiring an additional 44 shares during the period. Checchi Capital Advisers LLC raised its holdings in shares of Cencora by 2.2% in the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock worth $499,000 after buying an additional 48 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Cencora by 3.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company’s stock worth $353,000 after buying an additional 51 shares during the period. Tevis Investment Management grew its position in Cencora by 4.9% in the second quarter. Tevis Investment Management now owns 1,476 shares of the company’s stock valued at $333,000 after acquiring an additional 69 shares during the period. Finally, Horizon Bancorp Inc. IN grew its position in Cencora by 9.6% in the second quarter. Horizon Bancorp Inc. IN now owns 809 shares of the company’s stock valued at $182,000 after acquiring an additional 71 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Down 0.0 %

Shares of COR stock traded down $0.04 during trading hours on Friday, reaching $237.56. The company had a trading volume of 215,521 shares, compared to its average volume of 1,355,120. Cencora, Inc. has a 1-year low of $171.65 and a 1-year high of $247.66. The company has a 50 day moving average of $231.79 and a 200 day moving average of $232.87. The firm has a market cap of $47.38 billion, a price-to-earnings ratio of 25.99, a P/E/G ratio of 1.68 and a beta of 0.45. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.53.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.92 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 13.56 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a dividend of $0.51 per share. The ex-dividend date was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is currently 22.32%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Robert W. Baird raised their price target on Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. boosted their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Finally, Leerink Partners restated an “outperform” rating and set a $275.00 target price on shares of Cencora in a report on Thursday, June 27th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $258.63.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares in the company, valued at $2,656,970.12. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is currently owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.